SK bioscience Co.,Ltd. (KRX:302440)
South Korea
· Delayed Price · Currency is KRW
54,000
-400 (-0.74%)
At close: Dec 5, 2025
SK bioscience Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 4, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 4,231,934 | 3,948,704 | 5,528,451 | 5,643,627 | 17,212,500 |
| Market Cap Growth | 6.33% | -28.57% | -2.04% | -67.21% | - |
| Enterprise Value | 3,877,324 | 2,813,918 | 4,326,779 | - | - |
| Last Close Price | 54000.00 | 50400.00 | 72000.00 | 73500.00 | 225000.00 |
| PE Ratio | - | - | 247.72 | 46.09 | 48.47 |
| Forward PE | - | - | - | 24.69 | 23.37 |
| PS Ratio | 6.78 | 14.76 | 14.96 | 12.36 | 18.53 |
| PB Ratio | 2.04 | 1.95 | 3.25 | 3.24 | 10.75 |
| P/TBV Ratio | 2.48 | 2.34 | 3.27 | 3.25 | 10.78 |
| P/FCF Ratio | - | - | - | - | 34.87 |
| P/OCF Ratio | 64.22 | - | 188.39 | - | 32.08 |
| EV/Sales Ratio | 6.21 | 10.52 | 11.71 | - | - |
| EV/EBITDA Ratio | - | - | 189.96 | - | - |
| Debt / Equity Ratio | 0.20 | 0.19 | 0.01 | 0.07 | 0.07 |
| Debt / EBITDA Ratio | - | - | 0.90 | 0.80 | 0.22 |
| Debt / FCF Ratio | - | - | - | - | 0.22 |
| Asset Turnover | 0.25 | 0.11 | 0.19 | 0.22 | - |
| Inventory Turnover | 3.34 | 1.63 | 1.70 | 1.35 | - |
| Quick Ratio | 3.53 | 4.34 | 9.56 | 4.13 | 3.68 |
| Current Ratio | 4.27 | 5.08 | 10.20 | 4.69 | 4.00 |
| Return on Equity (ROE) | -0.13% | -2.69% | 1.29% | 7.33% | - |
| Return on Assets (ROA) | -3.08% | -3.69% | -0.38% | 3.38% | - |
| Return on Capital (ROIC) | -3.48% | -4.18% | -0.42% | 4.04% | - |
| Return on Capital Employed (ROCE) | -4.70% | -5.50% | -0.70% | 6.50% | 28.70% |
| Earnings Yield | -0.14% | -1.36% | 0.40% | 2.17% | 2.06% |
| FCF Yield | -3.17% | -7.41% | -0.26% | -3.51% | 2.87% |
| Buyback Yield / Dilution | -2.00% | -0.24% | 0.01% | -4.32% | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.